Development and Validation of a Clinical Trial Patient Stratification Assay That Interrogates 27 Mutation Sites in MAPK Pathway Genes

Open Access

Peer-reviewed

Research Article

Ken C. N. Chang ,

Contributed equally to this work with: Ken C. N. Chang, Stefan Galuska

* E-mail: ken.chang@merck.com

Affiliation Clinical Development Laboratory, Merck & Co, Inc., Rahway, New Jersey, United States of America
⨯
Stefan Galuska ,

Contributed equally to this work with: Ken C. N. Chang, Stefan Galuska

Affiliation Clinical Development Laboratory, Merck & Co, Inc., Rahway, New Jersey, United States of America
⨯
Russell Weiner,

Affiliation Clinical Development Laboratory, Merck & Co, Inc., Rahway, New Jersey, United States of America
⨯
Matthew J. Marton

Affiliation Clinical Development Laboratory, Merck & Co, Inc., Rahway, New Jersey, United States of America
⨯

Reader Comments (0)

Mutation detection
Is the Subject Area "Mutation detection" applicable to this article?

Thanks for your feedback.
Polymerase chain reaction
Is the Subject Area "Polymerase chain reaction" applicable to this article?

Thanks for your feedback.
Nucleotides
Is the Subject Area "Nucleotides" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Thyroid carcinoma
Is the Subject Area "Thyroid carcinoma" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Oligonucleotides
Is the Subject Area "Oligonucleotides" applicable to this article?

Thanks for your feedback.
Primer extension assay
Is the Subject Area "Primer extension assay" applicable to this article?

Thanks for your feedback.